Healthy immune system immunological memory Deuterated water labelling of specialized T cell subsets
Conditions
Interventions
A dose of booster vaccine of either TWINRIX-Adult, Boostrix-IPV or M-M-RVaxProvaccine that will be given to participants of group I as a tool to provoke an immune response of the already existing memo
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Feasibility pre-group Ia: Having previous record of vaccination against either poliomyelitis, measles, Hepatitis A or Hepatitis B and being seropositive to one of these antigensAge between 18-40 years Are able to understand a written informed consent formAre able to follow the protocol of the study during the study period.For study group I To be eligible for inclusion in study group I cohort of this study, a subject must meet all of the following criteria: Participants - Are healthy - Have vaccination history with either TWINRIX, MMR or IPV and being seropositive for one of the vaccines. - Are above the age of 18 - Are able to understand a written informed consent form - Are able to follow the protocol of the study during the study period - Willing to undergo pregnancy testing (3 tests) before and during the deuterated water consumption phase. For study group II To be eligible for inclusion in study group II cohort of this study, a subject must meet all of the following criteria: Participants -Are healthy - Are between the age of 18-40 years - Are able to understand a written informed consent form - Are able to follow the protocol of the study during the study period - Willing to undergo pregnancy testing (3 tests) before and during the deuterated water consumption phase.
Exclusion criteria
Exclusion criteria: Pregnant, uncertain about pregnancy status, currently breastfeeding, chronic infection or autoimmune disease, immunocompromised, use of immunomodulatory drugs, use of immunosuppressant medications, self-reported anemia (group I). For more detailed criteria see C1 Onderzoeksprotocol section 4.4.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Turnover rate of antigen-specific cells (group I) 2. Turnover rate of functional T-cell subsets (group II) | — |
Secondary
| Measure | Time frame |
|---|---|
| Determining absolute numbers of antigen (polio, measles, HepA and HepB) specific T cells during the study Monitoring cytokine profile and IgG antibody levels in blood in response to the vaccine | — |
Countries
Netherlands
Contacts
Public ContactJ.A.M Borghans
Universitair Medisch Centrum Utrecht
Outcome results
None listed